Comparison of Carvedilol and Atorvastatin for Preventing of Contrast-Induced Nephropathy.

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-05-15. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cardiacpatientsagentunstabledose of
  Phrases that lowered it: effectevaluateatorvastatinbetween 18blood pressure
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Blinding: single (lowers risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 8.9% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 212472 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 40579 (raises risk) · Drug's FDA history
• Maximum age: 65 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 70.5% (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• PrevenTion of Contrast-inducEd nephroAThy With urinE Alkalinization NCT02980003 · started 2015 · scored riskier than 64% of active trials completed
• High Dose Atorvastatin for Preventing Contrast-induced Nephropathy NCT02114346 · started 2013 · scored riskier than 27% of active trials completed
• The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy NCT03627130 · started 2018 · scored riskier than 83% of active trials completed
• The Acetylcysteine for Contrast-Induced Nephropathy Trial NCT00736866 · started 2008 · scored riskier than 54% of active trials completed
• Efficacy of Vitamin E in Preventing Contrast-Induced Acute Kidney Injury Following Coronary Angiography NCT02070679 · started 2014 · scored riskier than 48% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.